Clinical Trial Update: Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 trial updating low-dose interleukin-2 for acute respiratory distress syndrome related to COVID-19 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• IL-2 (Interleukin-2)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: COVID 19 | Phase 2 | Status: COMPLETED